(Q37848651)

24 August 2017

1 reference

title

Determinants of interferon β efficacy in patients with multiple sclerosis (English)

1 reference

24 August 2017

0 references

0 references

1

Joep Killestein

1 reference

24 August 2017

Chris H Polman

2

1 reference

PubMed ID

21364522

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

24 August 2017

Nature Reviews Neurology

1 reference

24 August 2017

7

1 reference

24 August 2017

4

1 reference

24 August 2017

221-228

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2011.22

24 August 2017

0 references

cites work

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Predicting responders to therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Imaging biomarkers in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

IFN-beta pharmacogenomics in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Antibodies against interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Measures in the first year of therapy predict the response to interferon β in MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

The fragile benefit of BENEFIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Predictive markers for response to interferon therapy in patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Glypican 5 is an interferon-beta response gene: a replication study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.22

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364522

12 December 2020

inferred from PubMed ID database lookup

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21364522

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NRNEUROL.2011.22

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kv7v7xakqzdc7kgclewi4jmt6e

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_kv7v7xakqzdc7kgclewi4jmt6e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kv7v7xakqzdc7kgclewi4jmt6e

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/kv7v7xakqzdc7kgclewi4jmt6e

30 July 2022